Open AccessTreatment of hyperprolactinemia: A single-institute experience
Author(s) -
Tse-Yu Chen,
Chung-Hsin Lee,
MengYin Yang,
ChiungChyi Shen,
Yin-Ping Yang,
Yueh Chien,
Yingwei Huang,
Chih-Ming Lai,
Wen-Yu Cheng
Publication year - 2021
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.535
H-Index - 42
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000584
Subject(s) - cabergoline , medicine , bromocriptine , tolerability , prolactinoma , dopamine agonist , prolactin , dopaminergic , gastroenterology , dopamine , hormone , adverse effect
Dopamine agonists such as bromocriptine and cabergoline have been found to be an effective treatment for hyperprolactinemia, not only inducing adenoma shrinkage but also lowering serum prolactin levels. Among known dopamine agonists, cabergoline is the drug of choice due to its enhanced tolerability compared with bromocriptine. This study aimed to evaluate cabergoline's effectiveness, along with transsphenoidal surgery, in the treatment of hyperprolactinemia.